Richard Hogan, MD
Internal Medicine · Sewickley, PANPI 1588680375
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 63 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $507 and has fallen 87.8% since, to $62 in 2025.
Across 63 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$216
- GSK$209
- Lilly USA, LLC$102
- Novo Nordisk$86
- AbbVie$83
- Pfizer$49
- plus $253 from 11 others
What the payments were for
- Food & beverage$997100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 11 | $216 |
| GSK | 17 | $209 |
| Lilly USA, LLC | 5 | $102 |
| Novo Nordisk | 6 | $86 |
| AbbVie | 5 | $83 |
| Pfizer | 3 | $49 |
| Astellas Pharma US Inc | 2 | $48 |
| Johnson & Johnson(2 entities) | 3 | $47 |
| Merck | 3 | $42 |
| Exact Sciences | 1 | $18 |
| Gilead | 1 | $17 |
| Boehringer Ingelheim | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Vivus LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
| Sunovion Pharmaceuticals Inc. | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$997 in reported general payments places this provider in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 49 | $58,462 |
| EliquisApixaban | 51 | $49,782 |
| JardianceEmpagliflozin | 50 | $49,520 |
| MounjaroTirzepatide | 27 | $34,853 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $14,042 |
| MyrbetriqMirabegron | 11 | $12,977 |
| XareltoRivaroxaban | 11 | $11,932 |
| Repatha SureclickEvolocumab | 14 | $7,267 |
| EntrestoSacubitril/Valsartan | 11 | $6,736 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,189 |
| SynthroidLevothyroxine Sodium | 68 | $3,826 |
| Atorvastatin Calcium | 295 | $2,715 |
| Midodrine Hcl | 13 | $2,651 |
| Losartan Potassium | 177 | $2,588 |
| Levothyroxine Sodium | 202 | $2,501 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $86 | $58,46249 claims |
| PfizerEliquis | $49 | $49,78251 claims |
| Boehringer IngelheimJardiance | $16 | $49,52050 claims |
| Lilly USA, LLCMounjaro | $102 | $34,85327 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $209 | $19,23127 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $12,97711 claims |
| Johnson & JohnsonXarelto | $47 | $11,93211 claims |
| AbbVieSynthroid | $83 | $3,82668 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Sewickley
- Jonathan EpsteinPhiladelphia$13.1M
- Pitamber DevgonPhiladelphia$7.5M
- Daniel RaderPhiladelphia$1.7M
- Mohammed KidwaiBala Cynwyd$894K
- Ronak BhimaniNorristown$623K
- David GoldmannPhiladelphia$525K
- Christopher StillDanville$442K
- Jeffrey FreidLower Gwynedd$425K
- Cheryl PegusSpring House$370K
- Eyob FeyssaPhiladelphia$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.